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ABSTRACT: CD14 is a multifunctional receptor expressed on many cell types and has been shown to mediate immune response resulting
in the activation of an inflammatory cascade, with polymorphism of its promoter (rs2569190) found to be associated with susceptibility
to several diseases. In malaria infection, the CD14 gene demonstrated a pathogenic profile in regulating experimental cerebral malaria,
with reports of elevated levels of soluble CD14 in serum of patients but no definitive conclusion. We present a detailed analysis of genetic
diversity of CD14 promoter gene (snp −159 C/T; rs2519190) polymorphism between a malaria-infected group and uninfected controls and its
association with clinical parameters of disease. Genomic DNA samples obtained from 106 Plasmodium falciparum malaria–infected patients
and 277 uninfected controls were elucidated with a polymerase chain reaction-restriction fragment length polymorphism (RFLP) assay.
Our results show a significant diversity (P = 3.32E−06) in the genotypic frequency (3.8% versus 22.4%) of the rs2569190 mutant variant
between the malaria-infected group and controls, respectively. The mutant allele had the lowest frequency among the malaria-infected group
demonstrating its necessity for infection. Mean parasitemia (parasites/μL of blood) was significantly regulated based on CD14 polymorphic
profile (19 855 versus 37 041 versus 49 396 for homozygote mutants, heterozygotes, and homozygote wild type, respectively). Interestingly,
we found no association between CD14 genetic variants with fever, age of patients, or anemia. How this affects disease severity between
subregional and continental groups deserves further clarification, including extending these studies in a larger group and among severe and
asymptomatic patients with malaria.
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Introduction

Inflammatory reactions, secondary to pathogenic stimuli, are
important for the initiation of necessary immune response for
combating the external stimuli when effectively and efficiently
deployed. Infection with Plasmodium falciparum, the causative
agent of malaria, especially common in sub-Saharan Africa,1,2
is one such pathogen for which the inflammatory cascade
would be necessary, considering possible infection severity,
especially in nonimmune travelers or children.3–5 Several innate
immunity genes have been implicated, at one time or another,
as having significant roles in disease severity, infection outcome, or development of possible sequelae, postinfection.6 One
such gene is CD14, a coreceptor to the toll-like receptor
(TLR)-4/MD2 complex on leukocytes,7–10 and expressed on
many cell types. It has been demonstrated to mediate innate
immune response due to its specificity for bacterial lipopolysaccharide and consequent pro-inflammatory signaling and
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initiation of phagocytosis.11–13 It lends its capacity to T-cell
plasticity, driving a TH1 differentiation, especially with infections such as malaria.
In published reports, genetic variations leading to dysfunctional monocyte functions have been implicated in disease susceptibility and outcome, probably clarifying how human
populations have adapted to major infectious diseases through
the ages.14 Genetic variants of the CD14 gene (a C-to-T transition, snp −159 C/T) have been shown to be associated with
susceptibility to multiple diseases and conditions including
allergic rhinitis,15 functional dyspepsia,16 inflammatory bowel
disease,17 gram-negative bacteria, and respiratory infections,
including brucellosis.18–21 Its significance in allergic reactions
and outcome in patients with asthma have also been documented.21,22–24 In human, malaria infections particularly, elevated levels of soluble CD14 have been found in patients with
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acute infections,25 concluding that soluble CD14 levels may
play a critical role in disease severity. A murine infection model
has been the clearest to delineate a specific pathogenic role for
CD14 during experimental cerebral malaria infection, showing
a protective outcome in Plasmodium berghei–infected transgenic CD14 mice.9
Although differing outcomes have been reported for the
critical role of TLRs alongside CD14, its co-receptor, in mediating disease susceptibility or outcome in malaria infection,26–29
it is abundantly clear that this promoter gene potentially has a
significant role in disease outcome. Would CD14 promoter
gene (rs2519190) single-nucleotide polymorphism (SNP) be a
mediating factor in who develops severe or acute disease in
sub-Saharan Africa? Will the hereditary variants regulate initiation of immune response thereby affecting (positively or
negatively) phagocytosis and the inflammatory cascade following infection as well as clinical parameters of disease? Dissecting
the essentiality of CD14 promoter gene polymorphism in
acute P falciparum malaria–infected patients is imperative, necessary to bridge the existing knowledge gap.
Our objective is to investigate any association between
CD14-snp159 C/T (rs2569190) gene polymorphism and susceptibility to acute malaria infection or other measures of disease severity, such as parasitemia, fever, and anemia. To do this,
we conducted a detailed analysis of genetic diversity of CD14
promoter gene polymorphism in an infected group versus
uninfected controls, recruited from sub-Saharan Africa.
Genomic DNA samples obtained from 106 P falciparum
malaria–infected (microscopy and polymerase chain reaction
[PCR] confirmed) patients and 227 uninfected controls from
southwestern Nigeria were subjected to a PCR-RFLP analysis.
We evaluated association with parasitemia, age of patients,
fever, and anemia (packed cell volume [PCV]).
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purposes, whereas anemia was determined by PCV. Genomic
DNA was extracted from blood samples with a Qiagen Blood
Mini Kit, according to standard protocols (Qiagen Inc.,
Valencia, CA, USA). DNA elution volume of 100 μL total was
stored at −20°C, until further analysis. In addition, 277
genomic DNA samples, from same geographical location and
same ethnic mix (RDT and PCR negative for malaria infection), served as uninfected controls. This project was approved
by the University of Ibadan/University College Hospital
Institutional Review Committee (approval number UI/
EC/12/0279) and conducted in accordance with Helsinki
declaration of 1975. Fever was determined by measuring the
axillary body temperature. Anemia was determined by measuring the PCV, expressed as a percentage, whereas parasite
count was evaluated per microliter of blood by counting the
maximum number of parasite per 200 leukocytes multiplied
by 8000.

PCR confirmation for malaria infection
To confirm microscopy results, PCR assay targeting the 18S
ribosomal RNA gene of Plasmodium spp, with primers, protocols, and reaction setup, was conducted.31,32 Polymerase chain
reaction was performed on a Prime G thermal cycler (Bibby
Scientific, Staffordshire, UK) in a total volume of 25 μL and
amplified using 1× PCR buffer (20 mM Tris-HCl [pH 8.4],
50 mM KCl, and 1.5 mM of MgCl2), 0.125 mM of dNTPs,
0.25 mM of each primer, and 1 U Taq DNA polymerase (New
England Biolabs, Hitching, UK). About 5 μL of amplified
products was loaded onto 2% agarose gels (SeaKem Agarose,
Lonza, Rockland, ME, USA), and band size was determined
poststaining with SYBR Green 1 gel stain (Cambrex
Biosciences, East Rutherford, NJ, USA).

Materials and Methods
Subjects and demographics

Genotyping for CD14 promoter gene (rs2569190)
polymorphism

A total of 106 patients (age range: 6 months-5 years), who presented with presumptive, acute malaria infection (initial diagnosis positive for P falciparum by rapid diagnostic test [RDT])
at St Mary Catholic Hospital, from November 2013 to
November 2014, and whose parents/guardians provided
informed consent were recruited from Ibadan, south-western
Nigeria, to participate in this study. Rapid diagnostic test was
performed with the SD Bioline histidine-rich protein 2
(HRP-2) kit (Standard Diagnostics, Gyeonggi-do, Republic
of Korea), with parasite species detected according to manufacturers instruction. Patients, recruited from same geographical area, with similar ethnic mix (Yoruba) were examined, and
temperature reading, indicative of fever, was recorded.
Capillary blood from a finger prick was spotted onto Whatman
filter papers (GE Healthcare Bio-Sciences Corp, Piscataway,
NJ, USA), after sterilizing the fingertip with an alcohol swab.
Thin and thick blood smears were made for microscopy

To assay for the SNP of the CD14 promoter gene (rs2569190),
we used a previously published primer and protocol,33 with
some amendments. We amplified 1 μL of genomic DNA as
template, with conditions optimized to 25 μL of final volume,
as described.1 About 5 μL of PCR products was examined on a
2% ethidium bromide–stained agarose gel; positive amplification yielded products of 561 base pairs (bp) and size estimated
with a GeneRuler 100bp Plus DNA ladder (Thermo Fisher
Scientific Inc, Springfield Township, NJ, USA).

RFLP assay
To determine genotypic and allelic frequencies of the polymorphic variants, we set up a RFLP assay using the FastDigest
BsuRI enzyme (Thermo Scientific), following manufacturer’s
guidelines, as previously described.34 Digested products were
analyzed on a 3% agarose gel, and band sizes were determined,
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Table 1. Genotypic and allelic frequencies of CD14 (snp −159 C/T; rs2519190) promoter gene polymorphisms between patients with Plasmodium
falciparum–infected malaria and healthy, uninfected controls.
Polymorphism

Genotype

Malaria: n = 106 (%)

CONTROLS: n = 277 (%)

Odds ratio (95% CI)

P value

CD14 (rs2569190)

C/C

60 (56.6)

127 (45.8)

1.54 (0.96–2.48)

Reference

C/T

42 (39.6)

88 (31.8)

1.41 (0.86–2.30)

.15

T/T

4 (3.8)

62 (22.4)

0.14 (0.04–0.38)

3.32E−06

CD14 (rs2569190)

Allele

Malaria: n = 212 (%)

CONTROLS: n = 554 (%)

Odds ratio (95% CI)

P value

C

162 (76.4)

342 (61.7)

2.00 (1.38–2.94)

Reference

T

50 (23.6)

212 (38.3)

0.50 (0.34–0.72)

.00012

Abbreviations: C, cytosine; CD14, cluster of differentiation 14; CI, confidence interval; RDT, rapid diagnostic test; T, thymine.
Control group populations are individuals without malaria parasitemia and healthy control populations are individuals without malaria infection determined by RDT,
microscopy, and PCR and recruited from south-western Nigeria. C/T denotes alleles at the CD14 locus. Odds ratio was calculated by Fisher 2-tailed exact test. P < .05
was considered significant.

as described.1 Restriction analysis was conducted by 2 investigators, with 100% concordance. Homozygote wild-type variants (snp −159 C/C; rs2569190) produced bands of 204, 201,
and 156 bp, whereas homozygote mutant variants (snp −159
T/T; rs2569190) produced bands of 360 and 201 bp.

Statistical analysis
Tests for deviation from Hardy-Weinberg equilibrium (HWE)
were performed, with SNPs rejected based on the recommended threshold of P < .05 in control individuals.35 Differences
between malaria and control groups were assessed by odds
ratio. Original files were converted to an EH program format
to resolve genotypic and allelic frequencies, as previously
described.30

Results

We examined the genetic diversity of the CD14 gene promoter
(−159 C/T; rs1800829) SNP that has been demonstrated to
exhibit significant relevance within and between disease groups
and evaluated its association with disease outcome in P falciparum malaria–infected patients. To do this, we subjected
genomic DNA samples extracted from malaria-infected
patients (n = 106) and control group (n = 277) to a PCR-RFLP
assay. Genotypic frequencies at each variant were compatible
with the HWE (P > .05). Our results show that there is a widespread diversity in the genotypic frequency of the CD14 promoter gene between malaria-infected and control populations,
with this diversity more pronounced in malaria-infected
patients but not among uninfected controls (Table 1). The
wild-type variant (snp −159 C/C) of the CD14 promoter gene
had a higher frequency in patients with malaria compared with
controls (Figure 1). In fact, the mutant variant (snp −159 T/T)
(depicting a nonsynonymous polymorphism and possibly functional significance) was extensively widespread and significantly diverse in its frequency between both groups (3.8%
versus 22.4% for malaria-infected and control groups, respectively; P = 3.32E−06). In other words, the mutant allele was less

Figure 1. Genotypic frequency of CD14 gene promoter polymorphism
(snp −159 C/T; rs2569190) between Plasmodium falciparum malaria–
infected patients and healthy controls. Amplified PCR products were
digested with FastDigest BsuRI restriction endonuclease (Thermo
Scientific, NJ, USA) and expressed on a 3% ethidium bromide–stained
agarose gel. Wild-type variant (snp −159 C/C) produced 3 bands (204,
201, 156 bp), whereas mutant variant (snp −159 T/T) produced 2 bands
(360 and 201 bp) on digestion. Marker: GeneRuler 100bp Plus DNA
ladder (Thermo Scientific). Black bars indicate patients with malaria; gray
bars indicate uninfected controls.

common among malaria-infected patients compared with
uninfected controls. Examining the allelic frequency of this
gene revealed a similar pattern to that for genotypic distribution, with the mutant allele significantly less frequent (Figure
2) than the wild-type variant (23.6% versus 38.3% for malariainfected and uninfected controls, respectively; P = .0001).
To determine whether the CD14 gene promoter genetic
diversity results correlate with markers of clinical disease or
severity, we evaluated parasite load (parasites/μL of blood),
fever (°C), anemia (PCV), and age (months) among malariainfected patients. We found no statistically significant difference or any association for age (mean age: 31.9 versus
38.7 months; P = .42), fever (mean temperature: 38.4°C versus
38.7°C; P = .70), or anemia (mean PCV: 29.4% versus 31.7%;
P = .37) among malaria-infected patients with either the
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Figure 2. Allelic frequency of CD14 gene promoter polymorphism (snp
−159 C/T; rs2569190) between Plasmodium falciparum malaria–infected
patients and healthy controls. Amplified PCR products were digested with
FastDigest BsuRI restriction endonuclease (Thermo Scientific, NJ, USA)
and expressed on a 3% ethidium bromide–stained agarose gel. Black
bars indicate patients with malaria; gray bars indicate uninfected controls.

wild-type (snp −159 C/C) or mutant (snp −159 T/T) variants,
respectively. Surprisingly, we found mean parasitemia was
mildly significantly regulated (P = .07), based on CD14 gene
promoter polymorphic profile (19 855 parasites/μL of blood
versus 37 041 parasites/μL of blood versus 49 396 parasites/μL
of blood for patients with mutant, heterozygote, and wild-type
variants, respectively). This implies that among P falciparum
malaria-infected patients in sub-Saharan Africa, genetic diversity of the CD14 rs2569190 promoter gene is potentially a significant factor regulating parasite load and consequently disease
severity (Figure 3).

Discussion

Malaria is still a disease that confounds a lot of researchers
globally and the millions who fall sick to this infection constantly, especially considering the possibility of multiple infections in a single year. Despite the intensified efforts toward
designing a vaccine or new therapeutic regimen to replenish
the stock of available antimalarials, thereby reducing the
scourge of disease due to resistant parasites, there is a further
need for deconvoluting the various factors contributing to the
diversity in disease severity or susceptibility among endemic
populations. One of such potential factors is CD14, a leucinerich repeat surface protein linked to macrophage TLRs that
functions as a receptor for bacteria lipopolysaccharide and
microbial ligand recognition,14,18 as well as host response to
viral and fungal infections.36,37 Its polymorphism has been
shown to be a major regulator of innate immune response,10
and its demonstrated expression in the brain is a critical factor
in the development of cerebral malaria.9 Significantly, it has
been shown that CD14 genetic factors that affect differential
expression of downstream genes would potentially have functional imperative in the immune response to infectious pathogens or immunological diseases.10 To this end and as part of

Figure 3. Mean parasite distribution between patients with malaria with
either (A) wild-type (−159 C/C) or mutant (−159 T/T) variants and (B)
wild-type (−159 C/C+C/T) versus mutant (−159 T/T) variants of the CD14
gene promoter polymorphism (snp −159 C/T; rs2569190).

our ongoing work on immune regulatory patterns contributing
to disease diversity and severity, we set out to determine the
role, if any, of the genetic diversity of CD14 gene promoter
polymorphism (snp −159 C/T; rs2519190) on markers of clinical disease or severity among and between P falciparum
malaria–infected patients from sub-Saharan Africa. We found
that the polymorphism was equally distributed, showing no
deviations from HWE (P > .05) within malaria-infected and
control groups, implying our result is not due to selection pressure, that can be attributed to the disease.
Even though there are a number of publications referencing
CD14 and its regulatory or contributory role in several conditions and diseases, including allergy, just a handful is directly
related to malaria. A signature publication on murine cerebral
malaria showed that deletion of the CD14 gene confers protection against disease and a negative effect on parasite growth in
transgenic mice challenged with P berghei ANKA9 and recommended that this observation be elucidated in human infections. Our result among P falciparum malaria–infected
individuals confirm this finding, whereby the wild-type variant
of CD14 gene promoter polymorphism had the highest
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statistically significant genotypic and allelic frequencies among
patients with malaria when compared with uninfected controls.
In addition, the mutant variant was less frequent in malariainfected patients compared with the higher frequencies in
uninfected controls. This observation has significant implications for disease susceptibility among endemic populations and
could potentially clarify clinical differences or degrees of disease severity in subcontinental population groups across subSaharan Africa. Examining this finding among Plasmodium
vivax malaria–infected groups within and outside sub-Saharan
Africa would be an added benefit of this present report.
Oakley et al also reported on the beneficial role of CD14 in
regulating parasitemia among CD14 transgenic and wild-type
P berghei ANKA–infected mice, with the transgenics showing
2-fold reduction in parasitemia postinfection as well as longer
survival rate. This is a very interesting and significant finding
superbly confirmed by our result in human infection. We found
the highest mean parasitemia among malaria-infected individuals with the CD14 gene promoter wild-type variant and a
2.5-fold reduction (mildly significant) in mean parasitemia
among individuals with the mutant variant. This is very important considering the significance of immune regulatory markers in initiating immune response to antigenic stimuli. Despite
the fact that Togbe et al38 saw no conferred protection by the
loss of the CD14 gene in murine cerebral malaria, this present
finding clarifies possible differences between human and
murine infections, and potential benefit of the CD14 gene in
human P falciparum infection, not seen in animals (multiple
backcrosses, differing genetic background, parasite lines/
clones), which are completely different from field infections.
In addition, although Wenisch et al25 reported that they
found no relationship between soluble CD14 and markers of
disease severity in malaria infection, our present result states
otherwise, based on genetic diversity analysis. Our results qualitatively delineate the potential reasons for the results obtained
by Wenisch et al. This is an excellent study that should move
this field further, especially among malaria-infected individuals
from differing ethnic or endemic backgrounds or while examining severity of infection among nonimmune travelers from
nonendemic regions. We recommend further studies with
larger sample sizes and different population groups across subSaharan Africa.
The results in this study further confirm reports that
CD14 polymorphism potentiates a TH1 differentiation and
subsequent IFN-γ response leading to reduced malaria parasitemia. We believe that a variant CD14 would drive a deficient response leading to an immune cascade that could
potentially make disease worse, leading to complications,
compared with a normal immune response, in which infection can be adequately managed or controlled. Such complications could potentially include high-circulating immune
complex levels,1 extensive parasite diversity,39 incomplete
clearance of parasites posttreatment and potential for recrudescence,2 or possibly development of drug-resistant strains.
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To this end, it is imperative that our results be extended by
analyzing pro-inflammatory biomarkers in serum assays
from similar patient groups as well as patients with cerebral
or severe malaria, in addition to clarifying any contributory
role TLR polymorphisms may play in regulating disease
markers. In addition, we advocate strengthening awareness
and understanding of CD14 regulatory effects on innate
immune response, especially with malaria infection in subSaharan Africa, and potential to exacerbate disease outcome
among infected individuals carrying the CD14 promoter
gene mutant variant. We conclude that P falciparum malaria
severity in sub-Saharan Africa is significantly regulated by
CD14 promoter gene (snp −159 C/T; rs2569190) polymorphism, in addition to its importance for clinical disease,
markers of severity, and immune response. How this diversity
affects clinical presentation or disease severity between subregional or intercontinental population groups deserves further elucidation.
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